Sawka Anna M, Brierley James D, Tsang Richard W, Thabane Lehana, Rotstein Lorne, Gafni Amiram, Straus Sharon, Goldstein David P
Department of Medicine, Division of Endocrinology, University Health Network, Toronto, ON, Canada.
Endocrinol Metab Clin North Am. 2008 Jun;37(2):457-80, x. doi: 10.1016/j.ecl.2008.02.007.
Radioactive iodine remnant ablation (RRA) is used to destroy residual normal thyroid tissue after complete gross surgical resection of papillary or follicular thyroid cancer. The article updates a prior systematic review of the literature to determine whether RRA decreases the risk of thyroid cancer-related death or recurrence at 10 years after initial surgery, including data from 28 studies. No long-term randomized trials were identified, so the review is limited to observational studies. The incremental benefit of RRA in low risk patients with well-differentiated thyroid cancer after total or near-total thyroidectomy who are receiving thyroid hormone suppressive therapy remains unclear.
放射性碘残留消融（RRA）用于在乳头状或滤泡状甲状腺癌进行完整的肉眼手术切除后破坏残留的正常甲状腺组织。本文更新了之前对文献的系统评价，以确定RRA是否能降低初次手术后10年甲状腺癌相关死亡或复发的风险，纳入了28项研究的数据。未发现长期随机试验，因此该评价仅限于观察性研究。对于接受甲状腺激素抑制治疗的全甲状腺切除或近全甲状腺切除术后低风险分化型甲状腺癌患者，RRA的额外获益仍不明确。
